Journal article
Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series
Abstract
Generic agents do not require large clinical trials of safety and efficacy to enter the market, although they must demonstrate both pharmacological and bioequivalence to the brand name drug. Bioequivalence is attained when the extent of absorption of the generic falls within an FDA predefined range relative to the brand name drug. This potential variation in bioequivalence is not thought to be clinically meaningful, however, there are reports …
Authors
Van Ameringen M; Mancini C; Patterson B; Bennett M
Journal
Journal of Psychopharmacology, Vol. 21, No. 5, pp. 472–476
Publisher
SAGE Publications
Publication Date
July 2007
DOI
10.1177/0269881107077373
ISSN
0269-8811